News & publications
Company news and literature
Active intel
Industry deals in real time
We actively monitor global biotech financings and deals relevant to our pipeline.
- 30 Oct 2026Household exposure to symptomatic tuberculosis raises long-term TB risk in South African cohort
- 23 Oct 2026Africa: Gavi and Unicef Secure Lower Malaria Vaccine Price, Saving U.S.$50 Million for Childhood Immunization Programmes
- 22 Oct 2026Gavi secures 40% cut in malaria vaccine price, targets $50 million savings - Peoples Gazette Nigeria
September 2026 · Biointelect
Selected for Biointelect Venturer’s first cohort
Saccharide Therapeutics is one of six Australian infectious-disease companies entering Biointelect Venturer’s inaugural incubation program. The cohort shares $10.48 million in non-dilutive support, funded through the Australian Government’s Medical Research Future Fund. ST101 was named as a glycoconjugate malaria vaccine that targets a structure conserved across Plasmodium species and life-cycle stages — with the potential for broader protection than existing vaccines.
Biointelect Venturer31 August – 2 September 2026 · AVVCC26
At Australia’s Vaccine Value Chain Conference
Saccharide joined Biointelect Venturer’s pre-conference workshop and Australia’s 2nd Vaccine Value Chain Conference in Sydney. The workshop, held at the Sheraton Grand Sydney Hyde Park on 31 August, brought SMEs and translational researchers together on regulatory and commercialisation pathways before the main meeting on 1–2 September.
AVVCC26October 2025 · Vaccine
An SSCV potentiates BCG against tuberculosis
Co-administration of a synthetic saccharide conjugate vaccine (SSCV) with BCG provided synergistic protection in murine tuberculosis — the first in-vivo efficacy study of an SSCV against TB.
Open publication